Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir
Ключови думи
Резюме
Дати
Последна проверка: | 07/31/2016 |
Първо изпратено: | 02/24/2015 |
Очаквано записване подадено: | 05/09/2015 |
Първо публикувано: | 05/12/2015 |
Изпратена последна актуализация: | 08/15/2016 |
Последна актуализация публикувана: | 10/09/2016 |
Дата на първите подадени резултати: | 04/07/2016 |
Дата на първите подадени резултати от QC: | 08/15/2016 |
Дата на първите публикувани резултати: | 10/09/2016 |
Действителна начална дата на проучването: | 04/30/2014 |
Приблизителна дата на първично завършване: | 12/31/2014 |
Очаквана дата на завършване на проучването: | 12/31/2014 |
Състояние или заболяване
Интервенция / лечение
Drug: pitavastatin
Drug: placebo
Фаза
Групи за ръце
Arm | Интервенция / лечение |
---|---|
Experimental: Treatment sequence A, B Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks | |
Experimental: Treatment sequence B, A Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks |
Критерии за допустимост
Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
Полове, допустими за проучване | All |
Приема здрави доброволци | Да |
Критерии | Inclusion Criteria: - aged ≥18 years - able to provide informed consent - had confirmed HIV infection - on ART including atazanavir 300 mg and ritonavir 100 mg each day in the regimens that were not changed within 12 weeks before the randomization - patients who had cholesterol level between 200 and 500 and LDL between 130 and 400 mg/dL without any lipid-lowering agent or discontinued the lipid-lowering agent at least 1 month prior to randomization Exclusion Criteria: - had the history of pitavastatin and/or the constituent of the drugs allergy - known history of myocardial infarction and/or ischemic stroke within 1 month prior to the randomization that would be endangered if we stopped the previous lipid-lowering agent before the enrollment - abnormal AST and ALT with level ≥5 times in asymptomatic patients or ≥3 times of upper normal limit (UNL) in symptomatic patients - pregnancy or breastfeeding - on cyclosporine which had major drug interactions with pitavastatin - patients who denied to join the study |
Резултат
Първични изходни мерки
1. Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir [12 weeks]
Вторични изходни мерки
1. Safety of Pitavastatin in HIV-infected Patients [12 weeks]